Topics

Companies Related to "TRIB1 Inhibition Macrophages Could Cardiovascular Disease Therapy Target" [Most Relevant Company Matches] [Advanced Search Results] RSS

13:41 EDT 3rd April 2020 | BioPortfolio

Here are the most relevant search results for "TRIB1 Inhibition Macrophages Could Cardiovascular Disease Therapy Target" found in our extensive corporate database of over 50,000 company records.

Showing "TRIB1 Inhibition Macrophages Could Cardiovascular Disease Therapy Target" Companies 1–25 of 4,900+

Relevant

Myogen, Inc.

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. We believe that our advanced understanding of the biology of cardiovascular disease combined with our clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, ...


miRagen Therapeutics, Inc.

Cardiovascular disease is the leading cause of death globally. Astonishingly, in the United States, every 37 seconds a person dies from cardiovascular disease. For survivors, life changes dramatically after an adverse heart event. Because of the significant toll that cardiovascular and muscle disease takes on patients, miRagen Therapeutics, Inc., was found...

MyoKardia, Inc.

MyoKardia is dedicated to revolutionizing the treatment of genetic cardiovascular disease. The company’s proprietary platform combines recent breakthroughs in muscle biology with leading-edge cardiovascular disease genetics. This personalized, genetically targeted approach focuses on the underlying cause of disease and has the potential to drastically...


Esperion

We discover and develop pharmaceutical products for the treatment of cardiovascular disease, which is disease of the heart and the body's blood vessels and related organs. We intend to commercialize a novel class of drugs that focus on a new treatment approach we call "HDL Therapy," which is based on our understanding of high density lipoprotein, or HDL, function. HDL is the primary facilitator of...

Vasomedical

Vasomedical Inc. provides superior medical products and services that address unmet clinical needs in the management of patients with heart disease. The company’s core technology, EECP® therapy, provides healthcare professionals a non-invasive therapy for patients suffering from cardiovascular diseases. EECP therapy helps patients and their families lead active and productive lives. With ov...

Semafore Pharmaceuticals

Semafore Pharmaceuticals is a private, clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule signal transduction inhibitors targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other serious diseases. In addition to SF1126, the Company is developing SF2626, a next-generatio...

Semafore Pharmaceuticals, Inc.

Founded in 2000, Semafore Pharmaceuticals is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule signal transduction inhibitors targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other serious diseases. The PI3K signaling pathway is vital to several biological process...

Tenaya Therapeutics

Tenaya Therapeutics is a privately-held biopharmaceutical company focused on developing potentially curative treatments for heart disease of various underlying causes. Headquartered in South San Francisco, Calif., Tenaya was founded in 2016 by world-leading scientists from the Gladstone Institute’s Cardiovascular Division and the University of Texas S...

Reprieve Cardiovascular

Reprieve Cardiovascular’s Guided Diuretic Therapy is designed to manage fluids during diuretic therapy for patients with Acute Decompensated Heart Failure (ADHF), and may relieve a number of symptoms related to this condition. The therapy has the potential to enable precise and predictable management of a patient’s fluid levels, guarding against ...

VLST Corp

VLST Corporation discovers and develops novel therapeutics for the treatment of inflammatory and autoimmune diseases. Disease areas in which the company’s technology may have utility include multiple sclerosis, lupus, cardiovascular disease, diabetes and obesity. The company has already identified eight novel disease targets and is currently evaluating three of these targets for their therapeu...

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AA...

Casep

Our group of cardiologists provide individualized care in all aspects of Cardiovascular Disease. Our multiple office locations throughout Delaware, Chester, and Montgomery counties have been staffed and designed with your comfort as our primary goal.CASEP, P.C. provides care using state-of-the-art equipment and the latest procedures available in cardiovascular medicine. We also offer clinical prog...

Nuvelo

Nuvelo, Inc. is a publicly traded biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes several acute cardiovascular and oncology programs. The cardiovascular portfolio includes three programs: alfimeprase, a direct acting thr...

Reprieve Cardiovascular, Inc.

Reprieve Cardiovascular’s Guided Diuretic Therapy is designed to manage fluids during diuretic therapy for patients with Acute Decompensated Heart Failure (ADHF), and may relieve a number of symptoms related to this condition. The therapy has the potential to enable precise and predictable management of a patient’s fluid levels, guarding against ...

Rocket Pharmaceuticals, Ltd.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (A...

Reflow Medical Inc.

Reflow Medical, Inc. is a private company focused on empowering physicians through the design and development of innovative and effective technologies for cardiovascular disease. Reflow is developing a family of products to treat cardiovascular disease. The Temporary Spur Stent System is an investigational device only and is not currently approved for sale.

Aadi Bioscience, Inc.

Aadi is a clinical stage biopharmaceutical company led by Dr. Neil Desai, an inventor of ABRAXANE and the albumin-based technology platform. Aadi’s lead product nab-sirolimus (sirolimus albumin-bound nanoparticles for injectable suspension, ABI-009) is an mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation, mTO...

The Lipoprotein(a) Foundation

Because approximately 63 million Americans have high Lipoprotein(a) and are at risk of premature cardiovascular disease, the vision for the foundation is: To live in a world where high Lipoprotein(a) is routinely diagnosed, treated and family screened. The mission is to prevent cardiovascular events due to high Lipoprotein(a) by diagnosing this inherited r...

Aterovax SA

Aterovax is developing innovative products for the cardiovascular disease market based on a unique understanding of atherosclerosis, the condition responsible for most cardiovascular problems. Aterovax’s first product is a diagnostic blood test to measure activity of secretory phospholipase A2 (sPLA2), a powerful biomarker that provides physicians wit...

Cardiovascular Consultants, Ltd.

Cardiovascular Consultants, Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate cardiovascular care to achieve quality of life. Today Cardiovascular Consultants has 38 physicians and 15 mid-level providers in 17 locations, and is one of the largest cardiovasc...

Aviir, Inc.

Founded in 2005 by cardiologists and researchers from the Stanford University School of Medicine , Aviir is focused on the discovery, development and commercialization of innovative diagnostic and predictive cardiovascular tests, employing state of the art laboratory diagnostic methods. Aviir’s CLIA laboratory in Irvine, CA offers a range of tests for...

Cardiovascular Consultants Ltd.

Cardiovascular Consultants Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate cardiovascular care to achieve quality of life. Today Cardiovascular Consultants has 36 physicians and 14 mid-level providers in 15 locations, and is one of the largest cardiovascu...

Infinity Pharmaceuticals, Inc.

Infinity is an innovative drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs in the inhibition ...

KineMed, Inc.

KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag™ and KineMarker™) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. The Company is working to develop drug...

Syngenix Limited

SynGenix Limited SynGenix has developed technologies that effectively target drugs and drug discovery tools to the anatomical and cellular sites of origin of disease processes. SynGenix can delivery probes such as antisense in vivo for > drug target validation and systems for targeting small drugs and macromolecules to the site of disease. The core platform technologies have been demonstrated by...


More From BioPortfolio on "TRIB1 Inhibition Macrophages Could Cardiovascular Disease Therapy Target"

Quick Search

Corporate Database Quicklinks